Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Comparison of beclomethasone/formoterol and fluticasone/salmeterol fixed combinations for weekly asthma control Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016
Healthcare costs are reduced when asthma is treated with budesonide and formoterol in a single inhaler compared with the same medication via separate inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 54s Year: 2001
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
How does the Novolizer fit into the choice of inhaler? Source: Annual Congress 2005 - Asthma management - important issues Year: 2005
Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Can asthma be adequately treated with only one inhaler? Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003
An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Efficacy of montelukast as complementary therapy to fixed association ICS/LABA in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004
Evaluation of adherence of patients with asthma to treatment by single combination inhaler Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
The fluticasone/salmeterol combination product is superior to montelukast as first-line asthma control Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007